Last reviewed · How we verify
Palmitoleic Acid + Infliximab
Palmitoleic acid enhances the anti-inflammatory effects of infliximab, a TNF-α inhibitor, by modulating immune cell function and reducing systemic inflammation.
Palmitoleic acid enhances the anti-inflammatory effects of infliximab, a TNF-α inhibitor, by modulating immune cell function and reducing systemic inflammation. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
At a glance
| Generic name | Palmitoleic Acid + Infliximab |
|---|---|
| Sponsor | Chinese Medical Association |
| Drug class | TNF-α inhibitor + fatty acid combination |
| Target | TNF-α receptor (via infliximab); GPR120 and other metabolic sensors (via palmitoleic acid) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Palmitoleic acid is a monounsaturated fatty acid that promotes alternative macrophage activation and reduces pro-inflammatory cytokine production. When combined with infliximab (a TNF-α neutralizing monoclonal antibody), it may potentiate immunosuppressive effects and improve clinical outcomes in inflammatory conditions by synergistic reduction of TNF-α signaling and enhanced resolution of inflammation.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Common side effects
- Infection (bacterial, fungal, tuberculosis)
- Injection site reactions
- Headache
- Gastrointestinal disturbance
- Lupus-like syndrome
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palmitoleic Acid + Infliximab CI brief — competitive landscape report
- Palmitoleic Acid + Infliximab updates RSS · CI watch RSS
- Chinese Medical Association portfolio CI